Skip to main content
| News

Roche launches new coronavirus antibody test

18.09.2020

Roche is launching on the market a new antibody test to determine coronavirus infections. This should help with the development of vaccines. In addition, a drug from the Basel-based pharma giant has proven to be effective against coronavirus-associated pneumonia.

Roche Headquarter in Basel

Roche is launching a new antibody test that will identify people to have already been infected with coronavirus whose bodies have now developed antibodies against the virus. The test should help in developing vaccines against SARS-CoV-2. In specific terms, the test focuses on antibodies against the spike protein of SARS-CoV-2. The majority of vaccine candidates are aimed at inducing an antibody reaction against the spike protein.

The test will initially be launched in countries that accept that CE mark of the European Union (EU), as detailed in a press release. Roche has, however, also applied for Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA). The new test is actually the Basel-based pharma group’s twelfth coronavirus test in its testing portfolio.

In addition to launching a new test, Roche has also announced a success in relation to its drug Actemra/RoActemra. This has proven to be successful in treating patients suffering from pneumonia linked to a coronavirus infection. Patients that were administered Actemra/RoActemra in addition to the standard treatment, were 44 percent less likely to require ventilation or die as the disease progressed in comparison with those patients to receive only standard treatment and a placebo.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Ground-breaking oncology being developed in the Basel Area

The Basel Area – covering northwestern Switzerland – has seen tremendous growth in recent years, and has become a true...

Read More
Genedata expanding its user network
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Genedata expanding its user network

The Japanese biopharmaceutical firm Ajinomoto is to use the Genedata solution to accelerate its drug development processes at its site...

Read More
Basel Area Business & Innovation, Invest

How Moderna is growing in Switzerland

The number one rule in real estate is “Location, Location, Location.” The global biotech company Moderna found its location in...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sandoz decides on Basel for headquarters

Sandoz AG will continue to have its headquarters in Basel as an independent company. The separation from Novartis is expected...

Read More
VectivBio sold for approximately 1 billion dollars
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

VectivBio sold for approximately 1 billion dollars

The takeover of VectivBio is now being finalized: the Boston-based firm Ironwood Pharmaceuticals, which specializes in gastrointestinal medicine, has agreed...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

University of Basel and RocketVax present new Covid vaccine

Researchers from the University of Basel have developed a new concept for a Covid vaccine in collaboration with the biotech...

Read More
1 2 3 64

Do you have a question? We'd like to hear from you.